{"id":"W2909334052","doi":"10.1200/jco.18.00766","title":"Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"Cilag; National Cancer Institute; Pharmacyclics; Genentech; Servier; Incyte; Celgene; LAM Therapeutics; Adaptive Biotechnologies; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Kite Pharma; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Cohort; Internal medicine; Refractory (planetary science); Transplantation; Surgery; Adverse effect; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001583478,0.0002233788,0.001783863,0.0002289553,0.00008355767,0.00001365404,0.0001575403,0.0003807417,0.0000696894],"category_scores_gemma":[0.001245813,0.0001492287,0.0005376448,0.0001383832,0.00004254155,0.0001743743,0.00003349977,0.0002383977,0.0000108805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005440255,"about_ca_system_score_gemma":0.001189769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000159963,"about_ca_topic_score_gemma":0.0001273801,"domain_scores_codex":[0.996182,0.0002465119,0.002531827,0.0003395032,0.0003123005,0.0003879151],"domain_scores_gemma":[0.9940827,0.003521002,0.001463057,0.0002281987,0.0004304396,0.0002745949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06389696,0.4322005,0.4086324,0.0001455779,0.000367651,0.0005509694,0.0008905597,0.00000323753,0.0000447575,0.00001257015,0.001598742,0.09165609],"study_design_scores_gemma":[0.4612438,0.2834924,0.2356888,0.0001459914,0.0008216157,0.00004428047,0.0003497222,0.0001648336,0.0000966271,0.00003371333,0.01777919,0.0001390335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950873,0.000141749,0.0001237168,0.0006695402,0.001421113,0.00227275,0.00004759773,0.00001467595,0.0002215302],"genre_scores_gemma":[0.9959486,0.0001385466,0.002089681,0.0008709481,0.000320729,0.0001042822,0.00003568232,0.00003306102,0.000458495],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3973469,"threshold_uncertainty_score":0.6085371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07914781576734928,"score_gpt":0.4257238446997092,"score_spread":0.3465760289323599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}